Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDIC

Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate brea

Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS Oculis and the National Mu

Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the

Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of th

HANGZHOU, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- UTStarcom Holdings Corp. (“UT” “UTStarcom” or th

Oculis Holding AG (NASDAQ: OCS - Get Free Report) has been given a consensus recommendation of "Mode

Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and rais

ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purcha

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the sto

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused o

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in O

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving lo

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst co

Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Ocu

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and main

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privose

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privose

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The FDA Division of Neurology provided positive

British outsourcer Mitie ‌has agreed to be acquired by rival OCS Group ​International for a ​total v

U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings

PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potent

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers

Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the

Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pri

Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to

Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the p

Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar

Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pr

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowe

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52

Guggenheim analyst Yatin Suneja initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rati

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and raises

Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the pr